GlassScriptPrepare for your visit
Kendra K Kay
Internal Medicine · Columbia, MD · NPI 1417923905
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$2,192.11
in general payments reported to CMS, 2019-2025 · $298 in 2025
The $298 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Who reported paying
General payments only, top 6 by amount.
- Novo Nordisk INC $288.56
- Astellas Pharma US INC $250.03
- Abbvie INC. $236.35
- Astrazeneca Pharmaceuticals LP $174.92
- Lilly USA, LLC $164.99
- Takeda Pharmaceuticals U.S.A., INC. $149.92
Drugs and devices associated with these payments
Veozah Jardiance Ozempic Rybelsus Auvelity Airsupra Varithena Administration Pack Opsynvi Uptravi Leqvio Wegovy Farxiga
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Kendra Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/63864/kendra-k-kay